Recent Quotes (30 days)

You have no recent quotes
chg | %

Hercules Capital Inc  

(Public, NYSE:HTGC)   Watch this stock  
Find more results for NASDAQ:HTGC
15.17
+0.06 (0.40%)
Feb 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 15.11 - 15.24
52 week 9.95 - 15.24
Open 15.15
Vol / Avg. 522,275.00/449,626.00
Mkt cap 1.18B
P/E 16.48
Div/yield 0.31/8.17
EPS 0.92
Shares 77.19M
Beta 0.90
Inst. own 47%
Feb 23, 2017
Q4 2016 Hercules Capital Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 7, 2016
Hercules Capital Inc at Wells Fargo Middle Market Opportunities Forum
Nov 29, 2016
Hercules Capital Inc at FBR Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 68.32% 27.31%
Operating margin 52.72% 46.78%
EBITD margin - 46.90%
Return on average assets 8.78% 3.27%
Return on average equity 16.59% 6.02%
Employees 63 -
CDP Score - -

Address

400 Hamilton Ave Ste 310
PALO ALTO, CA 94301-1805
United States - Map
+1-650-2893060 (Phone)
+1-650-4739194 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hercules Capital, Inc., formerly Hercules Technology Growth Capital, Inc., is a specialty finance company. The Company is focused on providing senior secured venture growth loans to venture capital-backed companies in a range of technology, life sciences and sustainable and renewable technology industries. The Company is an internally managed, non-diversified, closed-end investment company. The Company focuses its investments in companies active in the technology industry sub-sectors characterized by products or services, including computer software and hardware; networking systems; semiconductors; semiconductor capital equipment; information technology infrastructure or services; Internet consumer and business services; telecommunications; telecommunications equipment, and media. Within the life science sub-sector, the Company focuses on medical devices, bio-pharmaceutical, drug discovery, drug delivery, healthcare services and information systems companies.

Officers and directors

Manuel A. Henriquez Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark Robert Harris CPA Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Scott Bluestein Chief Investment Officer
Age: 36
Bio & Compensation  - Reuters
Melanie Grace Chief Compliance Officer, General Counsel
Age: 46
Bio & Compensation  - Reuters
Andrew Olson Vice President - Finance, Senior Controller
Age: 32
Bio & Compensation  - Reuters
Jennifer McKay Vice President of Human Resources
Bio & Compensation  - Reuters
Allyn C. Woodward Jr. Lead Independent Director
Age: 74
Bio & Compensation  - Reuters
Doreen Woo Ho Director
Age: 68
Bio & Compensation  - Reuters
Robert P. Badavas Independent Director
Age: 62
Bio & Compensation  - Reuters
Thomas J. Fallon Independent Director
Age: 54
Bio & Compensation  - Reuters